David Goel’s Ventyx Biosciences VTYX Stock Holding History

David Goel’s Portfolio VTYX Stock Details VTYX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q4	–	Sell	-89,900	Closed	-$3.12M	–	21
2023 Q3	$3.12M	Hold	89,900	–	–	0.04%	18
2023 Q2	$2.95M	Hold	89,900	–	–	0.03%	18
2023 Q1	$3.01M	Sell	89,900 -245,100	-73%	-$9.53M	0.04%	16
2022 Q4	$11M	Hold	335,000	–	–	0.21%	17
2022 Q3	$11.7M	Hold	335,000	–	–	0.22%	20
2022 Q2	$4.1M	Hold	335,000	–	–	0.09%	19
2022 Q1	$4.55M	Buy	+335,000	New	+$4.48M	0.05%	25

Other funds holding VTYX

Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

LGM

Logos Global Management San Francisco, California $2.32B AUM 536.01% 1-Year Est. Return

TCM

Tang Capital Management San Diego, California $2.2B AUM 156.35% 1-Year Est. Return

Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Opaleye Management Boston, Massachusetts $1.1B AUM 197.64% 1-Year Est. Return

David Goel's VTYX Position: Q4 2023 in Review

David Goel sold out of Ventyx Biosciences (VTYX) in Q4 2023, closing a stake of 89,900 shares — an estimated $3.12M sold.

David Goel first reported a position in VTYX in Q1 2022 and held it in 7 quarters. The position peaked at $11.7M in Q3 2022. 121 funds tracked by Wall St. Rank hold VTYX as of Q4 2023.

David Goel reported no remaining Ventyx Biosciences position as of Q4 2023 after selling out during the quarter.
David Goel sold 89,900 Ventyx Biosciences shares in Q4 2023, an estimated $3.12M.
David Goel first reported a position in Ventyx Biosciences in Q1 2022 and held it in 7 quarters.
David Goel's Ventyx Biosciences position peaked at $11.7M in Q3 2022.
121 funds tracked by Wall St. Rank held Ventyx Biosciences as of Q4 2023.

Based on Matrix Capital Management Company's 13F filing for Q4 2023, filed 13 Feb 2024.